West Pharmaceutical stock gains after strong Q2 figures and insider selling
Published on 09/16/2026 at 10:49 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS
West Pharmaceutical Services, Inc. stock (ISIN US9523901012) extended its recent rally with a closing price of USD 365.00 on September 15, 2026 on the New York Stock Exchange, marking a 2.76 percent gain for the day and underscoring investor confidence in the company’s latest quarterly figures.
Q2 2026 earnings beat expectations
West Pharmaceutical Services delivered strong results in the second quarter of 2026, with adjusted earnings per share of USD 2.37, beating the consensus estimate of USD 2.08 by USD 0.29 and highlighting solid operating performance according to MarketBeat on September 15, 2026.
Revenue in Q2 2026 reached USD 872.30 million, ahead of analyst expectations of USD 839.98 million and representing year-over-year growth of 13.8 percent, while net margin stood at 16.98 percent and return on equity at 20.11 percent, as reported by Yahoo Finance on September 15, 2026.
In the same quarter of the prior year, West Pharmaceutical posted earnings per share of USD 1.84, so the Q2 2026 EPS of USD 2.37 reflects an increase of USD 0.53 per share, underscoring a clear improvement in profitability according to MarketBeat.
Guidance and analyst context for 2026
Looking ahead, West Pharmaceutical has set its guidance for the third quarter of 2026 at earnings per share between USD 2.140 and USD 2.240, and for the full year 2026 at USD 8.850 to USD 9.050 per share, providing investors with a clear earnings range according to MarketBeat.
On average, research analysts forecast that West Pharmaceutical will post earnings per share of USD 8.93 for fiscal year 2026, aligning closely with the company’s guidance midpoint and suggesting that the market views the outlook as achievable, as noted by MarketBeat on September 15, 2026.
The stock carries a consensus rating of Moderate Buy with an average analyst price target of USD 379.08, indicating modest upside from the recent closing level and reflecting broadly positive sentiment on the name according to MarketBeat.
Insider selling and technical backdrop
Alongside the fundamental strength, recent insider activity has drawn attention, with a company vice president reported to have sold 2,500 shares in a transaction disclosed in mid-September 2026, a move that investors may watch as a potential signal on valuation according to MarketBeat on September 15, 2026.
Technical momentum has been favorable as well, with West Pharmaceutical shares recently climbing about 3.86 percent in a single session and trading above key moving averages, including the 20-day, 50-day and 200-day lines, which supports a bullish trend structure according to Traders Union on September 15, 2026.
Stock performance and valuation snapshot
Over the latest trading days, West Pharmaceutical stock has shown a steady upward move, with the closing price rising from USD 346.23 on September 11, 2026 to USD 355.20 on September 14, 2026 and then to USD 365.00 on September 15, 2026, representing a cumulative gain of about 5.4 percent across these three sessions based on data from an Investing.com price history overview as of September 15, 2026.
For investors, the combination of double-digit revenue growth in Q2 2026, a year-over-year EPS increase from USD 1.84 to USD 2.37 and a consensus Moderate Buy rating with an average target price of USD 379.08 provides a concrete framework to assess whether the recent share price around USD 365.00 adequately reflects the company’s earnings power and guidance.
West Pharmaceutical stock price as of last close
As of the last completed trading day on September 15, 2026, West Pharmaceutical stock closed at USD 365.00 on its primary listing on the New York Stock Exchange, following an opening price of USD 355.02, an intraday high of USD 370.67 and a low of USD 354.65, with a daily change of 2.76 percent and trading volume of approximately 981,890 shares according to Investing.com data.
West Pharmaceutical stock - key data
- Company: West Pharmaceutical Services, Inc.
- ISIN: US9523901012
- Ticker: WST
- Trading venue: NYSE
- Price (as of September 15, 2026): 365.00 USD
- Market capitalization: [value not provided] USD (as of September 15, 2026)
- Sector / Industry: Medical Instruments and Supplies
- Index membership: S&P 500
